Basic Cardiovascular Sciences 2019 Scientific Sessions

July 29–August 1, 2019
Westin Boston Waterfront | Boston, Massachusetts

Registration Information
Registration for BCVS 2019 opens March 5, 2019


See Registration Rates and Housing Rates
Abstract Submission
Abstract & Awards submission opens January 9, 2019.


2019 Programming

Keynote Speaker: Christine Seidman, MD, Brigham and Women’s Hospital, Boston

(Below, click on a day/date to collapse or expand):

Featured Sessions

  • Early Career Pre-Conference Session
  • HFpEF: Unraveling the Gordian Knot
  • Mechanisms of Mitochondrial Quality Control
  • Early Triggers of Heart Failure
  • Beyond Myocytes and Fibroblasts: Forgotten Cells of the Heart
  • Poster Session 1

  • Women in Science Breakfast
  • Heart Failure in a Dish: from iPSCs to Organoids
  • Emerging Discoveries in Myocardial Metabolism
  • The Future of Cardiac Fibrosis
  • Diabetes and Cardiomyopathies: Where are We Now and What is New?
  • Early Career Session:  Oh the Places You Can Go…With a PhD
  • Cardio Oncology: Protecting the Heart from Cancer Treatment
  • Cardiac Myofilaments: Mechanics and Regulations in Heart Failure
  • Pathways and Mechanisms of Apoptosis
  • Workshop: How to Effectively Interact with the NIH
  • Poster Session 2

  • Cardiac Arrhythmias: from Basic Mechanisms to Precision Medicine
  • Cardiac Inflammasome in Heart Failure
  • Rare Genetic Diseases of the Heart
  • Workshop: How to Talk to a Clinician from a Research Point of View
  • Outstanding Early Career Investigator Award Competition
  • New Frontiers in the Regulation of Cardiac Gene Expression
  • Promising Cardiovascular Research Abroad
  • Cross-talk Between Various Cell Types in Heart Failure
  • Top 5 Techniques to Advance the Cardiovascular Research
  • Poster Session 3

  • Aging and Cardiovascular Risk
  • Workshop: Social Media in Modern Cardiovascular Research
  • Machine Learning, Big Data and AI in Heart Disease
  • Development of Therapeutics for Heart Failure

About this Meeting

The 14th annual BCVS 2018 Scientific Sessions has become the premier conference for molecular cardiovascular biology and disease. Sponsored by the American Heart Association Basic Cardiovascular Sciences Council, the world’s leading organization of cardiovascular scientists, the conference attracts leading researchers in fields such as microRNAs, cardiac gene and cell therapy, cardiac development and most recently tissue engineering and iPS cells.

The planned agenda includes 15 fast-paced sessions during 3½ days, set in a forum that promotes the relaxed exchange and discussion of cutting edge research in molecular and translational cardiovascular biology and disease. The program includes a diversity of speakers representing the best cardiovascular scientists from around the world.

In addition, the symposium will be of great value to scientists and executives of pharmaceutical companies and biotechnology firms who are in the cardiovascular space.

Target Audience

  • Basic cardiovascular scientists
  • Molecular/cellular biologists
  • Physiologists
  • Translational investigators
  • Clinical trialists
  • Practicing cardiologists
  • Cardiovascular nurses and pharmacists

Learning Objectives

At the conclusion of the conference, participants will be able to:
  1. Discuss advances in the underlying mechanisms that contribute to pathological cardiac remodeling and development of targeted therapeutic strategies to improve outcomes for patients with CVD.
  2. Evaluate the most recent evidence on the pathophysiological mechanisms underlying myocardial perfusion injury, supporting the use of cardioprotective strategies, including advances in oxidative stress-activated mechanisms in CVD pathophysiology.
  3. Discuss recent advances in understanding the complex interplay between signal transduction cascades in modulating apoptotic and functional pathways (mitochondrial, ion channels, metabolism) to identify novel drug targets and preserve functional cardiac myocytes.
  1. Describe current research exploring the integrated role of novel "omics" technologies and "big data" analytics that may allow for precision medicine and may improve patient outcomes by examining more holistically the pathophysiological mechanisms underlying cardiovascular function.
  2. Discuss the importance of state-of-the-art clinically relevant reprogrammed human cellular and large animal model systems, including the challenges to bridge the gap between basic science and clinical application of these modalities for improving translational research and outcomes in patients with CVD.
  3. Discuss challenges and issues arising regarding the pursuit of cardiovascular research, including future research directions, issues of responsibility in research and the move towards translation into clinical practice.
  4. Describe recent and emerging advances into the genetic and molecular mechanisms driving cardiomyopathy and heart failure that are guiding the development of interventions such as targeted gene therapy and regenerative stem cell therapy.